



GOOD PEOPLE
for GOOD HEALTH

April 2, 2025

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G-Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

In line with J. B. Chemicals & Pharmaceuticals Limited's commitment to reduction in carbon emission and purchasing power requirements from renewable sources, the Board of Directors of the Company have today approved acquisition of upto 70,00,000 equity shares of Jamnagar Renewables One Private Limited of Rs.10/- each aggregating to Rs.7,00,00,000/- from Continuum Green Energy Limited in one or more tranches so as to enable consumption of power generated from a Group captive hybrid (Solar + Wind) power project.

The disclosure required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as Annexure-A.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

Annexure-A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S. No.	Particulars	Disclosure
1.	Name of the target entity, details in brief such as size, turnover etc.	Jamnagar Renewables One Private Limited(JROPL) JROPL is engaged in the business of generating electricity from renewable energy sources and proposes to build a 48.60 MW wind-solar hybrid power project at Jamnagar, Gujarat Turnover – Not applicable as it is new SPV.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
3.	Industry to which the entity being acquired belongs	Renewables Energy Generating Company
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is	In line with J. B. Chemicals & Pharmaceuticals Limited’s commitment to reduction in carbon emission and purchasing power requirements from renewable sources, the acquisition of

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

	outside the main line of business of the listed entity)	shares will enable to make an investment in a Group captive hybrid (Solar + Wind) power plant to save costs and fulfill its ESG commitments.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government/ regulatory approvals are required
6.	Indicative time period for completion of the acquisition	It is expected to complete acquisition by September 30, 2025.
7.	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	The Company will invest up to an amount not exceeding Rs. 7 Crores by way of purchase of equity shares.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Not exceeding 4% of equity share holding of JROPL
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	JROPL is engaged in the business of generating electricity from renewable energy sources and proposes to build a 48.6 MW wind-solar hybrid power project at Jamnagar, Gujarat. History of last 3 years turnover: Not applicable as it is new SPV. Country : India

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com